Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
An open-label, non-randomized, multi-centre, Phase I/II trial to assess the efficacy and
safety of 2 schedules of PXD101 in combination with idarubicin in patients with AML not
suitable for standard intensive therapy.